Disclosed are a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, a preparation and the use thereof in the preparation of a drug for treating diseases, disorders or conditions benefiting from the inhibition of the Bruton's tyrosine kinase activity. The compound of the present invention has anti-proliferative and inhibitory effects on tumor cell strains such as A549, MINO, OCI-LY10 and TMD-8, and shows an excellent anti-tumor activity in tumor models such as Mino subcutaneous xenografts, and can be applied in drugs for treating solid tumors or leukemia associated with cell proliferation in humans or animals. The compound of the present invention has good pharmacokinetic properties, and can be used in the oral treatment of solid tumors or leukemia associated with the cell proliferation in humans or animals or autoimmune diseases. The compound of the present invention has the property of a low hERG channel blockade.
